Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings

This publication has 25 references indexed in Scilit:

• Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics
  Cancer, 2004
• Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemetics
  Cancer, 2003
• Delayed Chemotherapy-Induced Nausea in Women Treated for Breast Cancer
  Oncology Nursing Forum, 2003
• A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis
  Cancer Chemotherapy and Pharmacology, 1996
• Frequency and Clinical Implications of Delayed Nausea and Delayed Emesis
  American Journal of Clinical Oncology, 1996
• On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993
  Annals of Oncology, 1996
• Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients
  European Journal Of Cancer, 1992
• Predictive Factors of Delayed Emesis in Cisplatin-Treated Patients and Antiemetic Activity and Tolerability of Metoclopramide or Dexamethasone
  American Journal of Clinical Oncology, 1991
• Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting
  Annals of Internal Medicine, 1990
• Comparison of the 5-Hydroxytryptamine₃(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis
  New England Journal of Medicine, 1990